A Renewed Sense of Optimism in Paradigm Medical (OTC:PDMI.PK)
Report : Stockhaven -
Paradigm Medical Rebounds as Investors Await Four New Devices (OTC:PDMI.PK)
The Medical device industry has been one of the most successful industries within 2008 and 2009, and 2010 should continue that trend. StocksHaven Investments profiles Paradigm Medical Industries, Inc. (OTC:PDMI.PK), a promising company who will soon begin to introduce the first of its four new ophthalmic diagnostic devices, the Paravue, during the remainder of 2009. Plagued by lawsuits, financial woes,
and poor management — the company has made a vast array of changes during late 2008 and 2009 leading to an invigorated interest in past and present shareholders. The company named Stephen Davis the new president, an individual with an impeccable ability to attain funds and grants for struggling institutions, alongside 20 years experience in the ophthalmic industry. Paradigm also has the only patented technology utilizing photon lasers for cataract removal and is poised to capture a niche market within the glaucoma and ultrasound microscopy fields. The glaucoma market alone is estimated to reach $4 billion in 2010. With a portfolio consisting of a total of 15 devices currently available, and 4 pending release with one expect by end of 2009, Paradigm seems to have positioned itself nicely for a rebound in the near future.
About Paradigm Medical Industries, Inc.
Paradigm Medical Industries, Inc. develops, manufactures, sources, markets and sells ophthalmic surgical and diagnostic instrumentation and related accessories, including disposable products. The Company’s surgical equipment is designed for minimally invasive cataract treatment. Its cataract removal system, the Photon laser system, is a laser cataract surgery system designed to be marketed as the next generation of cataract removal. The Company’s diagnostic products include a P2000 pachymetric analyzer, a P37 Ultrasonic A/B Scan, P40, P45 and P60 UBM Ultrasound Biomicroscopes, a P37 A/B Scan, two perimeters, the Blood Flow Analyzer, and the Glaid. The diagnostic ultrasonic products, including the P2000 pachymetric analyzer, the P37 Ultrasonic A/B Scan and the P40 UBM Ultrasound Biomicroscope were acquired from Humphrey Systems, a division of Carl Zeiss.
Disclosure: Short-term position in PDMI
To feature your publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit www.stockshaven.com/ir_contract/ for more info
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
Contact Information:
StocksHaven Investments
Contact Person:
Michael Vlaicu
Founder, Lead Investment Analyst
email: email
Web: www.StocksHaven.com
Author:
Michael Vlaicu
e-mail
Web: www.stockshaven.com
Phone: 4163126929
News 
Market Data 
Discover 
